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Abstract
Background: The level of viral diversity in an HIV-infected individual can change during the course of HIV infection,
reflecting mutagenesis during viral replication and selection of viral variants by immune and other selective pressures.
Differences in the level of viral diversity in HIV-infected infants may reflect differences in viral dynamics, immune responses,
or other factors that may also influence HIV disease progression. We used a novel high resolution melting (HRM) assay to
measure HIV diversity in Ugandan infants and examined the relationship between diversity and survival through 5 years of
age.
Methods: Plasma samples were obtained from 31 HIV-infected infants (HIVNET 012 trial). The HRM assay was used to
measure diversity in two regions in the gag gene (Gag1 and Gag2) and one region in the pol gene (Pol).
Results: HRM scores in all three regions increased with age from 6–8 weeks to 12–18 months (for Gag1: P=0.005; for Gag2:
P=0.006; for Pol: P=0.016). Higher HRM scores at 6–8 weeks of age (scores above the 75
th percentile) were associated with
an increased risk of death by 5 years of age (for Pol: P=0.005; for Gag1/Gag2 (mean of two scores): P=0.003; for Gag1/
Gag2/Pol (mean of three scores): P=0.002). We did not find an association between HRM scores and other clinical and
laboratory variables.
Conclusions: Genetic diversity in HIV gag and pol measured using the HRM assay was typically low near birth and increased
over time. Higher HIV diversity in these regions at 6–8 weeks of age was associated with a significantly increased risk of
death by 5 years of age.
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Introduction
In resource-limited countries, approximately half of all HIV-
infected children who do not initiate antiretroviral therapy die by 2
years of age [1]. While early antiretroviral treatment dramatically
decreases infant mortality [2], many resource-limited countries
lack established programs for treatment of HIV-infected infants,
and many infants in rural areas are not able to access care [3].
Maternal factors associated with mortality among HIV-infected
infants include high HIV viral load, advanced HIV disease, early
cessation of breastfeeding, and primary HIV infection [4,5,6,7].
Infant factors include HIV infection before one month of age, low
CD4 cell %, and high viral load [5,6]. Viral characteristics, such as
HIV subtype D [8], have also been associated with increased
mortality of HIV-infected infants in some studies.
Several studies have found an association between higher HIV
diversity (higher levels of genetic variation among HIV variants in
the viral population) and more rapid HIV disease progression in
adults [9,10,11,12,13]. In adults, higher HIV diversity prior to
antiretroviral treatment was also associated with less effective
virologic suppression following a strategic treatment interruption
[14]. Viral dynamics and immune responses to HIV infection
differ in infants, children, and adults with HIV infection. Those
factors are likely to influence HIV diversity. Relatively little is
known about the relationship between HIV diversity and disease
progression in infants and young children. Previous studies reveal
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18642that most HIV-infected infants have genetically homogenous viral
populations, indicating that one or a few HIV variants usually
initiate infant infection [15]. HIV diversity generally increases in
HIV-infected children over time [16], in response to immune and
other selective pressures. In one study, sequence-based analysis of
env in seven HIV-infected infants did not find an association
between HIV diversity and disease progression [17]. Other studies
(five to six infants each) found that greater diversification of env
sequences over time was associated with slower disease progression
[18,19,20].
To date, most studies of HIV diversity have been performed by
analyzing sequences from individual HIV variants. The cost and
complexity of those methods often limit the number of samples
that can be analyzed, and therefore the scope of the studies
performed. We recently developed a rapid assay for HIV diversity
based on high resolution melting (HRM) of DNA duplexes
[21,22]. This HRM assay is simpler, less expensive, and requires
less labor than traditional, sequence-based assays used to quantify
genetic diversity; therefore, it can more easily be applied to larger
sample sets. This assay uses a high resolution melting instrument
(LightScanner, Idaho Technology, Inc., Salt Lake City, UT) to
measure the range of temperatures at which DNA duplexes melt.
Results from the HRM assay are expressed as a single number, the
HRM score. In a reproducibility study, results obtained with the
HRM assay were not significantly affected by differences in the
HIV viral load of the plasma sample used for analysis (range: 2,000
to 50,000 copies/ml), the sample volume (100 vs. 500 ul), or the
maximum number of HIV RNA copies used for amplification of
DNA templates for HRM analysis (range 100 to 5,000 copies of
HIV RNA). Furthermore, DNA templates prepared using
replicate reverse transcription and amplification reactions had
similar HRM scores (coefficient of variation: 0.064) [see File S1].
There was very little variation in HRM scores obtained when the
same DNA templates were analyzed repeatedly over the course of
a year (intra-class correlation coefficient: 94% [95% CI: 89%,
98%]) [21].
In a previous study, we cloned and sequenced HIV from nine of
the infants described in this report (20 sequences from each infant
sample, collected at 6–8 weeks of age) and their mothers (50
sequences for each maternal sample, collected near the time of
delivery) [21]. The infants had relatively low HRM scores (median
4.3, range 4.2–5.3) and low sequence-based genetic diversity
(median 0.31%, range 0.10–1.60%), while the mothers had a
wider range of HRM scores (median 5.7, range 4.4–7.7) and
higher sequence-based genetic diversity (median 3.57%, range
1.69–5.85%) [21]. Overall, HRM scores were significantly
associated with sequence-based measures of HIV diversity,
including genetic diversity, sequence complexity, and Shannon
entropy [21]. In this study, we analyzed HIV diversity using the
HRM assay, and used those data to evaluate the relationship
between HIV diversity and disease progression in HIV-infected
Ugandan infants.
Methods
Source of samples used for analysis
Plasma samples were obtained from Ugandan infants in the
HIVNET 012 study (enrollment 1997–1999) [23,24]. This sub-
study included HIV-infected infants who received single dose
nevirapine (sdNVP) for prevention of mother-to-child transmis-
sion, as well as infants who received no antiretroviral drugs for
prophylaxis. None of the infants received any other antiretroviral
drugs for treatment or prevention of mother-to-child transmission
of HIV by 6–8 weeks of age. Plasma samples collected at 6–8
weeks of age were used for HRM analysis; 6–8 week samples
were available for 25 of 37 infants in the sdNVP arm and from all
six infants in the placebo arm who were HIV-infected by 6–8
weeks of age (total: 31 infants). HIV viral loads were obtained for
11 of the 31 6–8 week samples (median: 464,335 copies/ml;
range: 44,454 to 7,993,300 copies/ml); all of those 11 infants
were in the sdNVP arm of the HIVNET 012 trial. We used
100 ul of plasma to extract HIV RNA for HRM analysis and
used 1/5
th of the extracted HIV RNA to amplify the DNA
templates that were analyzed in the HRM assay. Therefore,
among the 11 samples with viral load data, the number of HIV
RNA copies used to prepare DNA templates for HRM analysis
ranged from 889 to 159,866 copies. Samples from 9 of those 11
infants were analyzed in the HRM assay validation study
described above [21].
Plasma samples collected at 12 and 18 months of age were also
available for a subset of the 31 infants; those samples were also
analyzed with the HRM assay. Those data were used to evaluate
the relationship between HRM scores obtained at 6–8 weeks, 12
months, and 18 months of age. Infants were followed in the
HIVNET 012 trial to 5 years of age. Clinical and laboratory data
for these infants and their mothers was obtained from the
HIVNET 012 trial database. Twenty-six (83.9%) of the 31 infants
had viral load data obtained at 14 weeks of age; those data were
used to adjust for HIV viral load when assessing the association
between high HRM score and survival.
Laboratory methods
HIV viral load and CD4 cell counts were determined in the
HIVNET 012 trial. In utero HIV infection was defined as having a
positive HIV culture or positive HIV RNA assay at birth.
HIV resistance testing was performed previously using the
ViroSeq HIV Genotyping System (Celera, Alameda, CA), as
described [25]. HIV subtyping was performed by phylogenetic
analysis of HIV pol sequences, as described [26], with the following
modifications: sequence alignments were generated using MegA-
lign (Lasergene 7, DNAStar, Madison, WI), and PHYLIP v3.66
was used for analysis.
The HRM assay was performed as described [21]. Briefly, PCR
products generated in the ViroSeq system were used as template
DNA. In each reaction, the region of interest was amplified in a
nested PCR reaction that included a fluorescent dye that was
incorporated into the amplified DNA duplexes. The primer
sequences and regions amplified are shown in Table 1 and
Figure 1. The Gag1 amplicon includes a portion of the coding
regions for gag p7 and gag p1. The Gag2 amplicon includes a portion
ofthe coding regions for gag p7, gag p1, and gag p6. The Pol amplicon
includes a portion of the coding regions for protease and reverse
transcriptase. The LightScanner instrument was used to warm the
samples over a melt range 68uCt o9 8 uC, and to monitor the change
in fluorescence that resulted as the DNA duplexes melted and the
fluorescent dye was released; this step of the analysis takes
approximately 10 minutes to perform. Data from the LightScanner
instrument were used to produce a melting curve for each sample
that displayed the change in fluorescence as a function of
temperature [-d(fluorescence)/d(temperature) plotted against tem-
perature]. Those curves were used to determine the number of
degrees of temperature over which melting occurred (defined as the
HRMscore)[21].Notethattheactualmeltingtemperaturesforeach
sample (e.g., temperature at which melting begins, peak melting
temperature, temperature at which melting is completed) are not
considered in determining the HRM score. Each DNA sample was
analyzed in duplicate; results were deemed acceptable if the HRM
scores from the duplicate assays differed by ,0.5.
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each region tested vary among viral populations from different
HIV-infected individuals, and also vary among individual HIV
variants (e.g., in cloned plasmids derived from individual viruses).
The HRM assay was specifically designed not to take these
temperatures into account, but instead to measure the number of
degrees over which melting occurs. This is based on prior
observations that homogeneous DNA duplexes melt over a fairly
narrow temperature range, while more complex mixtures of DNA
duplexes melt over a wider temperature range. The actual melting
temperatures are not relevant to the level of genetic diversity, but
instead reflect other features of the DNA, such as the specific DNA
sequence, GC content, the presence of GC-rich domains,
sequence length, etc.
HRM results were also obtained for control plasmids. Since
plasmids are clonal (i.e., they have little or no genetic diversity),
plasmid HRM scores serve as baseline values corresponding to the
lowest HRM scores that are obtained for each region analyzed.
Each of the plasmids used as a control in this study was derived
from a different individual; for this reason, differences in the HRM
scores for the plasmids tested are expected to be larger than the
differences that one would expect when comparing the HRM
scores from plasmids isolated from a single individual.
Statistical Methods
Summary statistics (median and range for continuous variables;
frequency distributions for categorical variables) were provided for
clinical and laboratory variables; comparisons used Fisher’s exact
test and the exact Wilcoxon rank sum test. Mean HRM scores at
three different HIV genomic regions in either plasmids or infant
samples from 6–8 weeks were compared using ANOVA. Logistic
regression modeled the probability of being in the high HRM
group (HRM score above the 75
th percentile) and assessed the
association between clinical and laboratory characteristics for
HRM scores measured at 6–8 weeks, using Firth’s penalized
likelihood approach to avoid bias in parameter estimates caused by
small sample size.
Log rank tests were used to compare Kaplan Meier survival
curves of infants categorized into high vs. low HRM groups (above
vs. below the 75
th percentile), based on the HRM score obtained
from their 6–8 week samples; this was done separately for each
region analyzed (Gag1, Gag2, Pol), for the mean HRM score for
the two gag regions, and for the mean for all three HRM regions.
The choice of breakpoint for the HRM scores was data driven,
chosen amongst the 25
th,5 0
th and 75
th percentile as best
discriminating the 5-year mortality outcome [see File S2]; the
75
th breakpoint values were 5.0 for Gag1, 4.8 for Gag2, and 4.3
Figure 1. Regions analyzed in the HRM assay. The figure shows the regions of the HIV genome analyzed in the HRM assay (Gag1, Gag2, Pol).
The HIV genome is represented by a non-shaded bar. The HRM amplicons are represented by shaded bars. LTR: long terminal repeat; PR: protease; RT:
reverse transcriptase.
doi:10.1371/journal.pone.0018642.g001
Table 1. Use of the HRM assay to analyze different regions of the HIV genome.
Region analyzed Gag1 Gag2 Pol
Corresponding region
in HXB2*
1998 - 2096 2071–2278 2373–2597
Primer sequences
Forward 59-AAATTGCAGGGCCCCTAGGAA 59-ACTGAGAGACAGGCTAATTTTTTAG 59-AAATGGAAACCAAAAATGATAG
Reverse 59-TTTCCCTAAAAAATTAGCCTGTCT 59-GGTCGTTGCCAAAGAGTGATTTG 59-CATTCCTGGCTTTAATTTTACTG
HRM amplicon size 99 bp 208 bp 225 bp
HRM scores for plasmids
a
Median (range)
3.8 (3.8, 3.8) 3.4 (3.2, 3.8) 3.5 (3.4, 3.5)
HRM scores for 6–8 week
old infants (n=31)
b,c
Median (range)
4.7 (4.4, 7.3) 4.2 (3.6, 6.3) 4.1 (3.3, 6.7)
HRM scores for 12 month
old infants (n=17)
c
Median (range)
5.2 (4.3, 7.1) 4.6 (3.8, 6.4) 4.3 (3.3, 5.9)
HRM scores for 18 month
old infants (n=15)
c
Median (range)
5.1 (4.6, 6.3) 4.9 (4.2, 7.8) 4.4 (4.0, 5.9)
aControl reagents; two subtype A plasmids and two subtype D plasmids.
bOne infant did not have an HRM result for the Pol region.
cThese HRM scores can be compared to those obtained in an observational study of 79 children in Uganda [51] (median age 4.7 years, range 0.6–12.4 years). In that
study, the median HRM score in the Gag2 region was 5.9 (range: 3.8–11.9).
doi:10.1371/journal.pone.0018642.t001
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five-year follow-up of the HIVNET 012 trial. One infant who
initiated antiretroviral treatment during the study was censored at
the time of treatment initiation.
A Cox proportional hazard model was used to assess the
association between high HRM score and survival, while adjusting
for viral load at 14 weeks of age (log10 scale). Linear mixed-effect
models that account for potential correlations among repeated
measures from the same subject were used to evaluate the
relationship between age and HRM scores obtained at 6–8 weeks,
12 months, and 18 months. All statistical analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Informed Consent
Guidelines of the U.S. Dept. of Health and Human Services
and the authors’ institutions were followed in the conduct of this
research. Approval for the HIVNET 012 study was obtained from
the National HIV/AIDS Research Council in Uganda and Office
of Human Subjects Research – Johns Hopkins Medicine
Institutional Review Boards. Written informed consent was
obtained from the women in HIVNET 012 prior to their
participation in the study.
Results
In the HIVNET 012 trial, 37 infants in the sdNVP arm and six
infants in the placebo arm were HIV-infected by 6–8 weeks of age.
Samples were available for analysis from 31 of those 43 infants.
Table 2 shows the characteristics of the 31 HIV-infected infants
included in the sub-study and the 12 infants who did not have
samples available for analysis. The only difference observed was
that a higher proportion of infants in the group not included in the
sub-study died during the follow-up period; however, this
difference was not statistically significant (P=0.05); none of those
infants died by 6–8 weeks of age, so death of those infants was not
related to their lack of inclusion in the sub-study. Most of those
infants had samples collected in the HIVNET 012 trial at the 6–8
week visit; the samples from HIVNET 012 were used for
Table 2. Characteristics of infants who were HIV-infected by 8 weeks of age (HIVNET 012 trial, Uganda, enrollment 1997–1999).
Variable
Infants included in
analysis (N=31)
Infants not included
in analysis (N=12) P value
Median infant CD4% at birth (range) 44.6 (20.7, 76.0) 39.3 (25.0, 52.5) 0.07
d
Median infant log10 HIV viral load at 14 weeks of age (range)
a 5.8 (4.7, 6.9) 6.0 (4.7, 6.9) 0.36
d
Median maternal CD4 cell count at delivery (range) 477 (101, 1352) 379 (14.0, 1014) 0.22
d
Median maternal log10 HIV viral load at delivery (range) 4.8 (3.9, 5.8) 5.0 (3.7, 5.7) 0.86
d
Maternal HIV subtype
A 11 (35.5%) 4 (33.3%) 0.17
e
C 1 (3.2%) 2 (16.7%)
D 10 (32.3%) 3 (25.0%)
Intersubtype recombinant 3 (9.7%) 3 (25.0%)
Unknown 6 (19.4%) 0 (0.0%)
Single dose NVP exposure
Exposed 25 (80.6%) 12 (100.0%) 0.16
e
Non-Exposed 6 (19.4%) 0 (0.0%)
Timing of infant HIV infection
b
HIV-infected in utero 20 (64.5%) 9 (75.0%) 0.72
e
HIV-infected after birth by 6–8 weeks 11 (35.5%) 3 (25.0%)
NVP resistance in infants at 6–8 weeks
c
No resistance 10 (47.6%) 3 (100%) 0.22
e
Resistance 11 (52.4%) 0 (0.0%)
Death (5 years)
No 16 (51.6%) 2 (16.7%) 0.05
e
Yes 15 (48.4%) 10 (83.3%)
Proportion breastfeeding
At 6 months of age 27 (87.1%) 10 (83.3%) 1.00
e
At 12 months of age 25 (80.6%) 10 (83.3%) 1.00
e
Initiated ART during HIVNET 012
Yes 1 (3.2%) 0 (0.0%) 1.00
e
aAmong 43 infants in the HIVNET 012 trial who were infected at birth or by 6–8 weeks, 36 had viral load data obtained at 14 weeks of age (26 included in the analysis
and 10 not included in the analysis). There was insufficient viral load data available from 6–8 weeks for meaningful statistical analysis.
bInfants with in utero HIV infection had a positive HIV DNA test at birth.
cFor 19 infants (10 included in the analysis and 9 not included), either a sample was not available for HIV genotyping or a result was not obtained.
dTwo-sided exact p-value, Wilcoxon rank sum test.
eTwo-sided p-value, Fisher’s exact test.
doi:10.1371/journal.pone.0018642.t002
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prior testing.
We used the HRM assay to measure HIV diversity in the gag
and pol genes (Gag1, Gag2, and Pol amplicons, Table 1 and
Figure 1). These three regions were selected because they are likely
to be subjected to different selective pressures. An advantage of
using these regions for HRM analysis is that the analysis can be
performed using DNA left over from HIV genotyping (resistance
testing). This is important, since infant samples are often very low
in volume. Our recent studies using the HRM assay to analyze
HIV diversity in adults confirms that individual genomic regions
(e.g., in gag, pol) diversify differently in different individuals
(submitted manuscript). Therefore, analysis of multiple genomic
regions may provide additional information relevant to biologic
correlates such as survival.
Most HIV infections in Uganda are caused by HIV subtypes A
and D. As a control, we first analyzed the HRM scores of two
subtype A and two subtype D plasmids (cloned HIV DNA). The
HRM scores of the plasmid controls were low (for all three
regions: median: 3.5, range: 3.2–3.8, Table 1). Because the
plasmids are clonal, these HRM scores provide baseline values
that reflect the stability of the duplexes amplified from the
different genomic regions (Gag1, Gag2, Pol) and their melting
characteristics, in the absence of significant genetic diversity.
Plasmid HRM scores obtained for the Gag1 region were slightly
higher than those obtained for the Gag2 region (mean
difference=0.38, P=0.008) and the Pol region (mean differ-
ence=0.35, P=0.011). HRM results for the Gag1 and Gag2
regions were obtained for all 31 infants in the sub-study at 6–8
weeks of age; one infant did not have an HRM result for the Pol
region due to amplification failure. The HRM scores of the infant
samples were higher than those obtained for the plasmid controls,
reflecting the natural genetic diversity of HIV viruses (Table 1;
P,0.0001 for Gag1, P,0.0001 for Gag2, P,0.0001 for Pol).
HIV viral loads were available for 11 of the 31 infant samples
from 6–8 weeks of age that were tested with the HRM assay;
those viral loads were high (see Methods), indicating that
sampling error was unlikely to account for the low level of
diversity measured in some infant samples; however, some infants
did not have viral load data obtained in the HIVNET 012 trial,
and insufficient plasma remained to perform this testing for those
infants. In the infant samples, as in the plasmid controls, the
HRM scores obtained for the Gag1 region were slightly higher
than those obtained for the Gag2 region (mean difference=0.50,
P=0.003) and the Pol region (mean difference=0.75,
P,0.0001). We evaluated the correlation between the 6–8 week
HRM scores in the Gag1, Gag2, and Pol regions [see Figure S1].
This analysis revealed an association between the Gag1 and Gag2
regions (r=0.47, p=0.008) and between the Gag2 and Pol
regions (r=0.41, p,0.0001), but not between the Gag1 and Pol
regions (r=0.25, P=0.184). However, while this analysis
revealed that while the low and middle range HRM scores were
tightly clustered, high HRM scores in one region were not
correlated with high HRM scores in the other region. This
suggests that the degree of genetic diversity in the viral
populations differed from one region to another, and supports
the approach of analyzing the mean of HRM scores from two or
three regions of the regions analyzed.
The association between clinical and laboratory variables and
HIV diversity was assessed using the individual HRM scores
obtained at 6–8 weeks for the Gag1, Gag2, and Pol regions, and
also mean HRM scores of the Gag1 and Gag2 regions, and mean
scores of all three regions. One variable examined was exposure of
infants to sdNVP near the time of birth; NVP exposure could
theoretically impact the diversity of the infant’s viral population,
either by causing bottlenecking of the population (through
selection of a limited number of resistant variants) or by increasing
diversity (through selection of diverse variants with resistance
mutations). We did not find an association between HRM scores
(above vs. below the third quartile) and sdNVP exposure; however,
the ability to detect a difference between HRM scores in sdNVP-
exposed vs. sdNVP-unexposed infants may have been limited by
the small number of sdNVP-unexposed infants enrolled into this
cohort (N=6). We also did not find an association between HRM
scores and the other variables examined, which included infant
CD4 cell count % at birth, infant HIV viral load at 14 weeks,
maternal CD4 cell count at delivery, maternal HIV viral load at
delivery, HIV infection in utero, infant NVP resistance at 6–8 weeks
of age, and HIV subtype (data not shown).
In this sub-study, survival was reduced among infants who had
higher HRM scores at 6–8 weeks. In Kaplan Meier analyses, this
association was not significant for the Gag1 or Gag2 regions
individually (Figure 2A and 2B), but was significant for the Pol
region (P=0.005) and for the composite analyses (P=0.003 for the
mean of results from Gag1 and Gag2; P=0.002 for the mean of
the results from all three regions). In multivariate proportional
hazard models that included HIV viral load at 14 weeks of age and
HRM score, higher HRM scores at 6–8 weeks (for Gag2, the
mean of results from Gag1 and Gag2, and the mean of results
from all three regions) were independently associated with death
(Table 3).
Of the 31 infants, 26 were alive at 12 months and twenty-one
(81%) of the 26 infants had samples available for testing from 12 or
18 months of age (17 and 15 infants, respectively). In the analysis
of longitudinal HRM scores, we found higher HRM scores were
associated with older age (Table 1, beta=0.37, P=0.005; for
Gag2: beta=0.47, P=0.006; for Pol: beta=0.24, P=0.016;
where beta is the estimated mean increase in the HRM score
associated with one year increase of age). In this group of infants
who were infected in utero or shortly after birth, age is likely to serve
as a proxy for time since HIV infection. Our validation studies
clearly show an association between HRM scores and different,
sequencing-based measures of HIV diversity, so it seems
reasonable to assume that the higher scores observed in samples
collected from infants at 12 and 18 months reflects mutation-
driven evolution of the viral population. However, we did not
sequence HIV variants from the 12- and 18-month samples.
Discussion
Our previous study of Ugandan mother-infant pairs, which
included nine infants in this study, confirmed that HRM scores are
significantly associated with sequence-based measures of HIV
diversity (genetic diversity, as well as complexity, and Shannon
entropy) [21]. When the HRM assay is used to analyze complex
molecular populations, such as DNA amplified from HIV in
clinical samples, the melting temperatures of the DNA duplexes
may be influenced by a variety of factors, including the number
and type of nucleotide mismatches and insertions/deletions in the
duplexes, as well as the proximity of those sequence differences to
each other and to the ends of the duplex [22]. For those reasons,
HRM scores are likely to provide a more comprehensive measure
of diversity than traditional, sequenced-based approaches based on
simple algorithms (e.g., the frequency of nucleotide differences in a
sequence set). Both synonymous and non-synonymous mutations
influence DNA melting and would be expected to influence HRM
scores. Both types of mutations occur frequently in HIV,
particularly in poorly conserved regions, such as HIV gag. The
HIV Diversity in Ugandan Infants
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deletions that would also be expected to influence HRM scores.
It is important to note that many sequence-based algorithms used
to measure HIV diversity ignore insertions and deletions (e.g., by
‘‘gap stripping’’ sequence data prior to analysis).
Melting curves can be generated using other instruments that
measure incorporation/release of a fluorescent dye, such as those
designed for real-time PCR. We chose to use the LightScanner
instrument for the HRM assay because it was specifically designed
for melt curve analysis and includes software specifically designed
Figure 2. Kaplan Meier plots showing the relationship between HRM scores obtained at 6–8 weeks of age and infant survival. The
figures show the Kaplan Meier analysis for survival and HRM scores. For this analysis, infants with HRM scores above the 75
th percentile (above the
third quartile, .Q3) were characterized as having high HRM scores (black dashed line), and infants below that cutoff were characterized as having low
HRM scores (grey line). The X axis shows the time since birth in days (infant age); the Y axis shows the survival probability. The number of infants still
alive in each group (#Q3, .Q3) at each time point is shown below each graph. (A) Gag1 region, (B) Gag2 region, (C) Pol region, (D) mean of the two
gag regions (Gag1/Gag2), (E) mean of all three regions (Gag1/Gag2/Pol).
doi:10.1371/journal.pone.0018642.g002
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that the LightScanner instrument has greater data density and
greater temperature accuracy than other instruments [27]. Greater
data density and use of the saturating LCG+ dye are key features of
the LightScanner system that improve the sensitivity and accuracy
of heteroduplex detection for applications such as ours that involve
measuring the width of the derivative melt curve, rather than the
peak melting temperature. The simplicity of the HRM assay (both
inperformanceanddata output)makesstudies like thisonepossible.
Note that this study included measurement of diversity in 31
samples collected at 6–8 weeks, 17 samples collected at 12 months,
and 15 samples collected at 18 months (63 samples total), each
analyzed in three different genomic regions. Furthermore, the
HRM assay provides a measure of diversity in the entire viral
population, which avoids the sampling bias that may be introduced
with analysis of a limited number of HIV clones.
Numerous studies have evaluated changes in HIV diversity that
occur during the course of HIV infection in adults [28,29,30,31].
In adults, while HIV infection is usually initiated by one or a few
HIV variants, some individuals are infected with multiple HIV
strains [32,33,34,35,36]. When multiple HIV variants are
transmitted, difference in the fitness of different HIV variants
and/or selective pressures act very early in infection to select one
or a few founder strains, leading to homogenization of HIV env
sequences [37]. Antibody responses begin to contribute to genetic
selection of HIV a few months after infection [38]. In the first few
years of infection, env diversity tends to increase in a linear fashion
[29,31]. At some point, env diversity may stabilize or even
decrease. Late in disease, env sequences often become homoge-
neous as the immune system collapses [29,31]. While less
information is available for other regions of the HIV genome, it
is clear that different HIV genes/gene products are subjected to
different selective pressures; for example, while env is the major
target for anti-HIV antibodies [39], gag selection is mediated
predominantly by cytotoxic lymphocytes (CTLs) [40]. Interesting-
ly, the homogenization that is seen very early in infection in env
does not appear to occur in gag [37]. Later in infection, HIV env
and gag evolution is convergent in some individuals [40,41].
The patterns of HIV diversification and homogenization are
likely to be different in infants and adults for several reasons. First,
vertical transmission results from exposure of infants to a single
source: HIV from the mother. In contrast, adults often have
multiple independent HIV exposures leading to HIV infection,
which could influence the multiplicity of HIV infection. There are
also marked differences in viral dynamics in infants and adults. In
adults, there is a rapid decline in viral load shortly after HIV
infection, and a viral load set point is usually established during the
first few months of HIV infection. In one study, higher HIV
diversitywas seen inwomenwith higherviral load setpoints[10].In
contrast, viral loads usually remain very high in infants during the
first year of life, and then decline slowly over the next few years of
HIV infection, usually remaining at levels higher than those seen in
adults [42,43]. These differences in viral dynamics may reflect the
significant differences in the immune systems of newborn infants
andadults.Also,infection ofadultsoccurs inthe contextofa mature
immune system. Antibody responses to HIV infection are typically
detected in the first few weeks following infection. In contrast, the
immune system in newborn infants is immature. Production of anti-
HIV antibodies generally occurs later in infants, which one reason
whyantibody-based assays arenot recommended for HIVdiagnosis
in children under 18 months of age [44]. Cellular responses to HIV
infection are also different in children and adults. Most HIV-
infected infants have deficient cytoxic T lymphocyte (CTL)
responses to HIV [45,46], and often have inadequate CD4 cell
count help [42,47]. These and other factors are likely associated
with observed differences in cellular populations during HIV
infection in adults vs. infants. In adults, a decline in CD4 cell count
is associated with disease progression; in contrast, in children under
5 years of age, a decline in CD4 cell % is a more reliable biomarker
of disease progression [48]. Furthermore, infection of infants with
variants that were able to escape the mother’s CTL response may
further hinder the infant’s ability to contain the virus [49]. For these
reasons, we feel that changes in HIV diversity over time, and the
relationship of HIV diversity to disease progression, are likely to be
different in pediatric and adult populations. In this study, HIV
diversity in infants measured using the HRM assay tended to
increase duringthe first12–18 monthsof life.We do not know if this
increase in HIV diversity over time reflects direct selective pressure
for evolution (e.g., a response to cytotoxic lymphocytes targeting gag
or pol epitopes [50]), linkage to another region that is the target of
Table 3. Association of HRM score and survival in univariate (unadjusted) models and multivariate (adjusted) models that included
HRM score and HIV viral load.
HRM score at 6–8 weeks N
Hazard Ratio (95% CI)
Unadjusted P N
Hazard Ratio (95% CI)
Adjusted
1 P
Gag1 31 2.0 (0.7, 6.0) 0.19 26 2.1 (0.7, 6.6)
2 0.19
2.6 (0.8, 9.2)
3 0.12
Gag2 31 2.5 (0.8, 7.3) 0.11 26 3.5 (1.1, 10.9)
2 0.03
2.4 (0.7, 7.8)
3 0.15
Pol 30 4.7 (1.4, 15.8) 0.01 25 3.4 (1.0, 11.9)
2 0.06
2.7 (0.7, 10.6)
3 0.15
Mean (Gag1, Gag2) 31 4.2 (1.5, 11.9) 0.006 26 8.7 (2.6, 28.6)
2 0.0004
3.4 (1.1, 10.8)
3 0.04
Mean (Gag1, Gag2, Pol) 30 4.6 (1.6, 13.2) 0.004 26 6.9 (2.1, 22.9)
2 0.002
1.7 (0.5, 5.3)
3 0.40
1Two covariates were included in each multivariate model: HRM score measured at 6–8 weeks of age (binary, #75
th percentile vs. .75
th percentile) and HIV viral load
measured at 14 weeks of age (log10 scale). N: number of infants included in the model; CI: confidence intervals
2Hazard ratio, 95% CI, and P value for HRM score at 6–8 weeks of age.
3Hazard ratio, 95% CI, and P value for HIV viral load at 14 weeks of age (log10 scale).
doi:10.1371/journal.pone.0018642.t003
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or natural accumulation of mutations in the HIV genome without
selective pressure.
The major finding in this study is that higher levels of HIV
diversity near the time of birth (higher HRM scores in specific
regions of the HIV genome) were significantly associated with
decreased infant survival. This association was seen in Kaplan
Meier analyses both for the HIV gag region (the mean of results for
Gag1 and Gag2) and the HIV pol region. In multivariate
proportional hazard models that included HIV viral load and
HRM score, higher HRM scores at 6–8 weeks (for Gag2, the
mean of results for Gag1 and Gag2, and the mean of results for all
three regions) were independently associated with death. Further
studies are needed to examine the association between HIV
diversity in other regions (e.g., HIV env) and infant survival.
This study differs from previous reports that examined the
association between changes in HIV diversity over time in HIV-
infected children and disease progression [17,18,19,20]. Those
studies included smaller numbers of children (five to seven in each
study), used sequence-based measures for diversity analysis,
analyzed the env region (rather than gag and pol), and focused on
changes in diversity over time, rather than the level of HIV
diversity early in infection. Further studies are needed to identify
factors that influence the genetic diversity of HIV in young infants.
In theory, maternal factors, such as high HIV viral load, high viral
diversity, advanced HIV disease, or a complicated delivery, could
be associated with exposure of the infant to a higher and/or more
diverse viral inoculum, which could lead to establishment of infant
infection with a greater number of distinct HIV variants. The
genetics of the infant (e.g., HLA type, co-receptor expression)
could also potentially influence the type and complexity of the viral
population early in infection. If the viral population in an infant
were more diverse, it might be more likely to escape immune and
other selective pressures, leading to more rapid HIV disease
progression. Alternatively, high levels of HIV diversity in young
infants may be a surrogate marker for infection with viral variants
that have more error-prone reverse transcriptase enzymes or
higher rates of HIV replication; viruses with those properties
might be more likely to escape immune or other selective
pressures, or might cause more immune destruction over time
because of increased viral replication.
We do note that the mortality in our cohort was lower than what
is usually seen among HIV-infected infants in sub-Saharan Africa.
In the HIVNET 012 trial (source of the samples used in this study),
the 5-year mortality was 55%, similar to the mortality seen in the
subset of infants analyzed in this report. The lower mortality of
infants in the HIVNET 012 trial could have reflected an effect of
antiretroviral drug prophylaxis or other factors, such as enrollment
into a clinical trial with access to free treatment for acute illnesses,
prophylaxis for other infections, immunization, and other care that
may have impacted their outcome. We also recognize certain
limitations of this study. These limitations include the small sample
size (31 children) and the fact that 25 of the 31 infants studied were
exposed to sdNVP prophylaxis, which could have influenced the
composition of the viral population; in this study, we did not find an
association between HIV diversity in any of the three genomic
regions studied and either sdNVP exposure or detection of NVP-
resistance mutations in the infant’s virus.
Infants in this study were infected with non-subtype B HIV
(subtypes A, C, D, and inter-subtype recombinant HIV). While we
did not find an association between HIV subtype and HRM score
in this study, further studies are needed to evaluate this issue. We
also note that HIV viral load data was not available for some of the
6–8 week samples analyzed in the HRM assay; one or more of
those samples may have had an unusually low viral load that could
have resulted in a spuriously low HRM score due to sampling
error. We also acknowledge that the choice of the breakpoint used
in the survival analysis (above vs. below the upper quartile) was
data driven. Further studies are needed to define the biologic basis
for the association of HIV diversity and survival in HIV infected
infants observed in this study, and to determine whether the
findings of this study can be generalized.
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Figure S1 Comparison of HRM scores in the Gag1,
Gag2, and Pol regions. The plots show data from the HRM
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Pol; right: Gag2 vs. Pol). The Pearson correlation was used to
compare the HRM scores in the regions tested.
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